Medacta Group SA

SWX:MOVE Stock Report

Market Cap: CHF 3.0b

Medacta Group Valuation

Is MOVE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOVE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHF 103.68
Fair Value
44.7% overvalued intrinsic discount
4
Number of Analysts

Below Fair Value: MOVE (CHF150) is trading above our estimate of fair value (CHF103.68)

Significantly Below Fair Value: MOVE is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOVE?

Key metric: As MOVE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MOVE. This is calculated by dividing MOVE's market cap by their current earnings.
What is MOVE's PE Ratio?
PE Ratio33.9x
Earnings€94.93m
Market Cap€3.22b

Price to Earnings Ratio vs Peers

How does MOVE's PE Ratio compare to its peers?

The above table shows the PE ratio for MOVE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.8x
SOON Sonova Holding
22.2x11.48%CHF 11.6b
STMN Straumann Holding
35.5x14.97%CHF 15.2b
YPSN Ypsomed Holding
22.9x4.69%CHF 4.4b
GALE Galenica
22.8x5.38%CHF 4.4b
MOVE Medacta Group
33.9x8.96%CHF 3.0b

Price-To-Earnings vs Peers: MOVE is expensive based on its Price-To-Earnings Ratio (33.9x) compared to the peer average (25.8x).

Price to Earnings Ratio vs Industry

How does MOVE's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MOVE 33.9xIndustry Avg. 27.2xNo. of Companies16PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MOVE is expensive based on its Price-To-Earnings Ratio (33.9x) compared to the European Medical Equipment industry average (27.2x).

Price to Earnings Ratio vs Fair Ratio

What is MOVE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOVE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.9x
Fair PE Ratio27.4x

Price-To-Earnings vs Fair Ratio: MOVE is expensive based on its Price-To-Earnings Ratio (33.9x) compared to the estimated Fair Price-To-Earnings Ratio (27.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOVE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 150.00
CHF 164.40
+9.60%
7.60%CHF 178.87CHF 148.58n/a4
Nov ’26CHF 148.80
CHF 164.40
+10.48%
7.60%CHF 178.87CHF 148.58n/a4
Oct ’26CHF 142.80
CHF 155.86
+9.14%
9.98%CHF 180.47CHF 132.32n/a5
Sep ’26CHF 149.20
CHF 156.73
+5.05%
8.35%CHF 177.03CHF 133.22n/a6
Aug ’26CHF 148.80
CHF 149.76
+0.64%
7.45%CHF 159.79CHF 131.98n/a6
Jul ’26CHF 134.00
CHF 144.82
+8.07%
6.47%CHF 161.28CHF 132.66n/a6
Jun ’26CHF 135.00
CHF 143.87
+6.57%
6.61%CHF 160.77CHF 132.24n/a6
May ’26CHF 133.20
CHF 146.41
+9.92%
7.14%CHF 161.05CHF 132.47n/a7
Apr ’26CHF 128.20
CHF 148.00
+15.44%
6.45%CHF 161.10CHF 134.65n/a7
Mar ’26CHF 131.20
CHF 145.17
+10.65%
6.77%CHF 160.14CHF 135.01n/a7
Feb ’26CHF 116.60
CHF 140.64
+20.62%
3.63%CHF 149.82CHF 134.89n/a6
Jan ’26CHF 106.60
CHF 139.92
+31.25%
3.51%CHF 148.57CHF 134.15n/a5
Dec ’25CHF 110.40
CHF 139.92
+26.74%
3.51%CHF 148.57CHF 134.15n/a5
Nov ’25CHF 113.60
CHF 139.71
+22.98%
4.21%CHF 149.11CHF 131.07CHF 148.805
Oct ’25CHF 122.40
CHF 138.59
+13.22%
3.95%CHF 147.93CHF 132.44CHF 142.807
Sep ’25CHF 130.00
CHF 140.13
+7.79%
3.75%CHF 150.12CHF 134.40CHF 149.207
Aug ’25CHF 126.00
CHF 140.13
+11.21%
3.75%CHF 150.12CHF 134.40CHF 148.807
Jul ’25CHF 123.00
CHF 139.19
+13.16%
4.17%CHF 148.77CHF 129.61CHF 134.007
Jun ’25CHF 122.80
CHF 143.01
+16.46%
5.59%CHF 155.92CHF 131.46CHF 135.007
May ’25CHF 111.40
CHF 143.01
+28.37%
5.59%CHF 155.92CHF 131.46CHF 133.207
Apr ’25CHF 122.40
CHF 142.18
+16.16%
5.41%CHF 154.22CHF 130.04CHF 128.207
Mar ’25CHF 127.00
CHF 140.59
+10.70%
7.27%CHF 156.49CHF 126.46CHF 131.207
Feb ’25CHF 131.20
CHF 138.68
+5.70%
7.04%CHF 152.47CHF 125.02CHF 116.607
Jan ’25CHF 125.60
CHF 133.43
+6.23%
10.77%CHF 152.89CHF 110.76CHF 106.605
Dec ’24CHF 116.80
CHF 132.35
+13.31%
12.01%CHF 156.22CHF 113.18CHF 110.405
Nov ’24CHF 108.00
CHF 132.35
+22.55%
12.01%CHF 156.22CHF 113.18CHF 113.605
CHF 164.4
Fair Value
8.8% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/20 04:27
End of Day Share Price 2025/11/20 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medacta Group SA is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
David AdlingtonJ.P. Morgan
Ilya BurganskyResearch Partners AG